BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld MedTech
  • BioWorld Asia
  • BioWorld Science
  • Data Snapshots
    • BioWorld
    • BioWorld MedTech
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Thursday, December 25, 2025
Home » Newsletters » BioWorld Science

BioWorld Science

April 19, 2017

View Archived Issues

Novartis and Allergan collaborate on phase IIb study in NASH

Read More

OncoMed reports endpoint not met in tarextumab study, discontinuation of brontictuzumab trial

Read More

ADDF investment supports progression of NDX-1017 towards phase I trials for Alzheimer's disease

Read More

argenx achieves preclinical milestone with ARGX-115 under AbbVie collaboration

Read More

BioSpecifics opens phase I study of Xiaflex for uterine fibroids

Read More

AAV8-whirlin restores balance and auditory function in preclinical model of Usher syndrome

Read More

Ionis and Ribo collaborate on RNA-targeted therapeutics in China

Read More

Interim results from a phase II trial of tetravalent dengue vaccine candidate

Read More

Regen identifies new series of compounds that activate NR2F6 nuclear receptor

Read More

Encouraging 24-week data reported from phase III study of burosumab in X-linked hypophosphatemia

Read More

Cardinal Health to acquire select businesses from Medtronic's PMR division

Read More

First report of a novel somatic mutation in PRKAR1A gene in Sertolli cell tumor

Read More

Nivalis Therapeutics and Alpine Immune Sciences to merge

Read More

Temple University, Cognition Therapeutics discover sigma-2 receptor ligands for Alzheimer's disease

Read More

Mateon reports interim data from FOCUS study of CA4P in platinum-resistant ovarian cancer

Read More

Cinclus Pharma enrolling participants in first-in-human trial of X-842

Read More

AstraZeneca targets Mcl-1 with AZD-5991 for hematological cancers

Read More

Argos updates status of ADAPT phase III trial of rocapuldencel-T in metastatic renal cell carcinoma

Read More

Ludwig Institute for Cancer Research identifies FEN1, ERCC5 and EXO1 nucleases inhibitors

Read More

Pfizer presents beta-secretase 1 inhibitors

Read More

The University of Florida discovers antimicrobial agents

Read More

ADX-102 granted U.S. orphan status for congenital ichthyosis

Read More

INCB-039110 receives FDA orphan designation for graft-versus-host disease

Read More

Vivace Therapeutics patents YAP1/TEAD interaction inhibitors

Read More

ADAMTSL3 found as a candidate biomarker in ischemic stroke

Read More

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for Dec. 24, 2025.
  • Today's news in brief

    BioWorld MedTech
    BioWorld MedTech briefs for Dec. 24, 2025.
  • Illustration of magnifying glass looking at cancer in the brain

    Researchers discover how glioblastoma tumors dodge chemotherapy

    BioWorld MedTech
    Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
  • Left: Anthony Fauci. Right: Transmission electron micrograph of HIV-1 virus particles

    HIV research is close to a cure but far from ending the pandemic

    BioWorld
    Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
  • Acute myeloid leukemia illustration

    Apollo’s APL-4098 shows potent antileukemic effects

    BioWorld Science
    Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld MedTech
    • Today's news
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Newco news
    • Opinion
    • Regulatory
    • Science
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/Metabolic
    • Immune
    • Infection
    • Neurology/Psychiatric
    • NME Digest
    • Patents
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2025. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing